**Guideline Page and Request** | **Panel Discussion** | **References** | **Vote**
--- | --- | --- | ---
**SARC-E (1 of 6) GIST** Internal request: Institutional Review comment requesting the panel to consider including pazopanib. | Based on the data in the noted reference, the panel consensus was unanimous to include pazopanib for GIST. | Ganjoo KN, Villalobos VM, Kamaya A., et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014 Jan;25(1):236-40. | 13 0 0 |